Khronicheskaya serdechnaya nedostatochnost' u bol'nykh sakharnym diabetom: sovremennye predstavleniya


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents data on the incidence of congestive heart failure, cardiovascular morbidity and mortality in a population of patients with diabetes mellitus (DM), pathogenic factors and features of clinical manifestations, and diagnosis of heart disease in the diabetes. Current recommendations for the treatment of DM, features of hypoglycemic therapy in heart failure, problems of management of diabetic patients with chronic heart failure are discussed in detail.

Full Text

Restricted Access

About the authors

O. A Ettinger

References

  1. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic implications. Endocrine Rev 2004;25 (4):543-67.
  2. Fuller J.H., Stevens L.K., Wang S.L. WHO Multinational Study Group. Risk Factors for cardiovascular mortality and morbidity: the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44(2):S54-S64.
  3. Gaede P., Vedel P., Parving H.H., Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the STENO type 2 randomized study. Lancet 1999;353:617-22.
  4. Bristow M.R., Gilbert E.M., Abraham W.T., for the MOCHA Investigators. Effect of carvedilol on left ventricular function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Eur Heart J 1996; 17(Suppl):78.
  5. Ryden L., Armstrong P., Cleland J.G.F., for the ATLAS Investigators. High dose ACE-inhibitor strategy is more effective than low-dose in diabetic patients with congestive heart failure. J Am Coll Cardiol 1999;33(A):188.
  6. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: the MERIT-HF Study. Lancet 1999;353:2001-07.
  7. Sanchez M.A. Prevention and Treatment of Congestive Heart Failure in Diabetic Patients. Rev Esp Cardiol 2002;55:1083-87.
  8. Fonarow G.C., Adams K., Strausser B.P. ADHERE (Acute Decompensated Heart Failure National Registry): rationale, design, and subject population. J Card Fail 2002;8:S49.
  9. Nichols G.A., Hillier T.A., Erbey J.R. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614-19.
  10. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.
  11. Domanski M., Krause-Steinrauf H., Deedwania P. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003;42:914-22.
  12. Bourassa M.G., Gurne O., Bangdiwala S.I., et al. Natural history and patterns of current practice in heart failure:the Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 1993;22:14A-19A.
  13. Mosterd A., Cost B., Hoes A.W. The prognosis of heart failure in the general population: the Rotterdam study. Eur Heart J 2001;22:1318-27.
  14. SOLVD investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
  15. Bell D. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26:2433-41.
  16. Мравян C.P., Калинин А.П. Патогенез артериальной гипертензии при сахарном диабете и побочные действия применяемых гипотензивных средств // Российский кардиологический журнал 2001. № 1. C. 35-39.
  17. Hayat S.A., Patel B., Khattar R.S., Malik R.A. Diabetic cardiomyopathy: mechanisms, diagnosis, and treatment. Clin Sci 2004;107:539-57.
  18. Ban C.R., Twigg S.M. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008;4:575-96.
  19. Voulgari Ch., Papadogiannis D., Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 2010;6:883-903.
  20. Avendano G.F., Agarwal R.K., Bashey R.I. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 1999;48: 1443-47.
  21. Erbas T., Erbas B., Kabakci G., et al. Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus. Clin Cardiol 2000;23:259-63.
  22. Шамхалова М.Ш., Чугунова Л.А., Шестакова М. В. Новые возможности инсулинотерапии сахарного диабета типа 2 // Consilium Medicum 2005. Т. 7. № 9. С. 737-39.
  23. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31(12):1-11.
  24. AACE/ACE Consensus statement on type 2 diabetes mellitus: an algorythm for glycemic control. Endocrine Practice 2009;6(15):540-59.
  25. Шестакова М.В. Современные международные и национальные рекомендации по применению инновационных сахароснижающих препаратов -инкретинов - в лечении сахарного диабета типа 2//Consilium Medicum 2011. Т. 13. № 12. С. 5-9.
  26. Ryden L., Armstrong P., Cleland J.G.F., for the ATLAS investigators. High dose ACE-inhibitor strategy is more effective than low-dose in diabetic patients with congestive heart failure. J Am Coll Cardiol 1999;33(A):188.
  27. O'Driscoll G., Green D., Maiorana A., et al. improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999;33:1506-11.
  28. Шестакова М.В. Артериальная гипертония и сахарный диабет: механизмы развития и тактика лечения //Сахарный диабет. 1999. № 3. С. 19-23.
  29. Шестакова М.В. β-блокаторы при метаболическом сендроме и сахарном диабете: соотношение риск/ польза // Consilium Medicum 2005. Т. 7. № 9. С. 720-25.
  30. Haak E.S., Usadel K.H., Kohleisen M., et al. The effect of a-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res 1999;58:28-34.
  31. Roy T.M., Broadstone V.L., Peterson H.R., et al. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. Diabetes Res Clin Pract 1990;10:91-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies